Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods

Yuxi Cheng; Zhengzheng Song; Juan Chen; Zhangui Tang; Baisheng Wang

Heliyon (Feb 2024)

Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods

Yuxi Cheng,
Zhengzheng Song,
Juan Chen,
Zhangui Tang,
Baisheng Wang

Affiliations

Yuxi Cheng: Xiangya Stomatological Hospital, Central South University, Changsha, 410008, China; Xiangya School of Stomatology, Central South University, Changsha, 410008, China; Clinical Research Center of Oral Major Diseases and Oral Health, 410008, Hunan, China
Zhengzheng Song: Xiangya Stomatological Hospital, Central South University, Changsha, 410008, China; Xiangya School of Stomatology, Central South University, Changsha, 410008, China; Clinical Research Center of Oral Major Diseases and Oral Health, 410008, Hunan, China
Juan Chen: Xiangya Stomatological Hospital, Central South University, Changsha, 410008, China; Xiangya School of Stomatology, Central South University, Changsha, 410008, China; Clinical Research Center of Oral Major Diseases and Oral Health, 410008, Hunan, China
Zhangui Tang: Xiangya Stomatological Hospital, Central South University, Changsha, 410008, China; Xiangya School of Stomatology, Central South University, Changsha, 410008, China; Clinical Research Center of Oral Major Diseases and Oral Health, 410008, Hunan, China
Baisheng Wang: Xiangya Stomatological Hospital, Central South University, Changsha, 410008, China; Xiangya School of Stomatology, Central South University, Changsha, 410008, China; Clinical Research Center of Oral Major Diseases and Oral Health, 410008, Hunan, China; Corresponding author. Xiangya Stomatological Hospital, Central South University. Changsha, 410078, Hunan Province, China.

Journal volume & issue: Vol. 10, no. 4
p. e25895

Abstract

Read online

Oral squamous cell carcinoma (OSCC) affects a large number of individuals worldwide. Despite advancements in surgery, radiation, and chemotherapy, satisfactory outcomes have not been achieved. In recent years, the success of drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) has led to breakthroughs in cancer treatment, but systematic summaries on their effectiveness against OSCC are lacking. This article reviews the latest research on the PD-1/PD-L1 pathway and the potential of combination therapy based on this pathway in OSCC. Further, it explores the mechanisms involved in the interaction of this pathway with exosomes and protein-protein interactions, and concludes with potential future OSCC therapeutic strategies.

Published in Heliyon

ISSN: 2405-8440 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Science: Science (General); Social Sciences: Social sciences (General)
Website: https://www.cell.com/heliyon/home

About the journal

Abstract

Keywords